サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1468056

RNA干渉ドラッグデリバリー市場レポート：用途、技術、地域別、2024～2032年

RNA Interference Drug Delivery Market Report by Application, Technology, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 135 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
RNA干渉ドラッグデリバリー市場レポート：用途、技術、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 135 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のRNA干渉ドラッグデリバリー市場規模は、2023年に841億米ドルに達しました。今後、IMARC Groupは、市場が2032年までに4,103億米ドルに達し、2024～2032年の間に18.7%の成長率（CAGR）を示すと予測しています。

RNA干渉ドラッグデリバリーは、遺伝子発現や突然変異を監視するための治療ソリューションを指します。RNAiドラッグデリバリーは通常、静脈注射、皮内注射、腹腔内注射、局所デリバリー法で投与されます。ナノ粒子、肺、核酸、アプタマーなどのドラッグデリバリー技術が含まれます。これらの技術は、真核生物における遺伝子機能の解析や、治療用遺伝子サイレンシングソリューションの開発にも利用されています。その結果、RNAiドラッグデリバリーは、感染症、慢性代謝疾患、心血管疾患、神経疾患、泌尿器疾患、腫瘍疾患、眼科疾患の治療に広く用いられています。

がんや心血管疾患（CVDs）などの慢性疾患や遺伝性疾患の世界の有病率の増加は、市場の成長を促進する重要な要因の一つです。さらに、このような病気にかかりやすい高齢者人口が増加していることも、市場の成長を後押ししています。これに伴い、コロナウイルス感染症（COVID-19）が世界中に広がり続けていることから、RNAiドラッグデリバリー技術に対する需要が大幅に増加しています。アプタマー薬剤デリバリーシステムなどの標的化デリバリー法は、ウイルス抗原の発現を阻害できる低分子干渉RNA（siRNA）によって誘導されるため、抗ウイルス薬の投与に絶大な支持を得ています。さらに、革新的な合成デリバリー・キャリアやバイオ・ベクターの開発など、さまざまな技術の進歩が市場の成長を促進すると予想されています。siRNAやマイクロRNA（miRNA）を含むナノキャリアは、個別化医薬品の開発や、変化した細胞分子や代謝産物の同定に極めて重要です。ナノ技術と分子診断のセグメントにおける広範な研究開発（R&D）活動を含むその他の要因は、医療インフラの全体的な改善とともに、市場をさらに牽引すると予想されます。

本レポートで扱う主要質問

  • 世界のRNA干渉ドラッグデリバリー市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • RNA干渉ドラッグデリバリーの世界市場におけるCOVID-19の影響は？
  • 主要な地域市場は？
  • 用途別の市場内訳は？
  • 技術別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界のRNA干渉ドラッグデリバリー市場の構造と主要参入企業は？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 RNA干渉ドラッグデリバリーの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：用途別

  • 感染症
  • 循環器
  • 腫瘍学
  • 神経内科
  • 眼科
  • 泌尿器科
  • 代謝疾患
  • その他

第7章 市場内訳：技術別

  • ナノ粒子
  • 肺
  • 核酸
  • アプタマー

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第9章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Alnylam Pharmaceuticals Inc.
    • Arrowhead Pharmaceuticals Inc.
    • CureVac AG
    • Dicerna Pharmaceuticals Inc.
    • Gradalis Inc.
    • Ionis Pharmaceuticals Inc
    • Merck & Co. Inc.
    • Moderna Inc.
    • Quark Pharmaceuticals Inc.（SBI ALApharma Co. Limited）
    • Silence Therapeutics Plc
    • Sirnaomics Inc.
図表

List of Figures

  • Figure 1: Global: RNA Interference (RNAi) Drug Delivery Market: Major Drivers and Challenges
  • Figure 2: Global: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Application (in %), 2023
  • Figure 4: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Technology (in %), 2023
  • Figure 5: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Region (in %), 2023
  • Figure 6: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 7: Global: RNA Interference (RNAi) Drug Delivery (Infectious Disease) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: RNA Interference (RNAi) Drug Delivery (Infectious Disease) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: RNA Interference (RNAi) Drug Delivery (Cardiology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: RNA Interference (RNAi) Drug Delivery (Cardiology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: RNA Interference (RNAi) Drug Delivery (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: RNA Interference (RNAi) Drug Delivery (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: RNA Interference (RNAi) Drug Delivery (Neurology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: RNA Interference (RNAi) Drug Delivery (Neurology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: RNA Interference (RNAi) Drug Delivery (Ophthalmology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: RNA Interference (RNAi) Drug Delivery (Ophthalmology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: RNA Interference (RNAi) Drug Delivery (Urology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: RNA Interference (RNAi) Drug Delivery (Urology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: RNA Interference (RNAi) Drug Delivery (Metabolic Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: RNA Interference (RNAi) Drug Delivery (Metabolic Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: RNA Interference (RNAi) Drug Delivery (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: RNA Interference (RNAi) Drug Delivery (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: RNA Interference (RNAi) Drug Delivery (Nanoparticle Drug Delivery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: RNA Interference (RNAi) Drug Delivery (Nanoparticle Drug Delivery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: RNA Interference (RNAi) Drug Delivery (Pulmonary Drug Delivery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: RNA Interference (RNAi) Drug Delivery (Pulmonary Drug Delivery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: RNA Interference (RNAi) Drug Delivery (Nucleic Acid Drug Delivery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: RNA Interference (RNAi) Drug Delivery (Nucleic Acid Drug Delivery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: RNA Interference (RNAi) Drug Delivery (Aptamer Drug Delivery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: RNA Interference (RNAi) Drug Delivery (Aptamer Drug Delivery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: North America: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: North America: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: United States: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: United States: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Canada: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Canada: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Asia Pacific: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Asia Pacific: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: China: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: China: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Japan: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Japan: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: India: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: India: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: South Korea: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: South Korea: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Australia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Australia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Indonesia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Indonesia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Europe: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Europe: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Germany: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Germany: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: France: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: France: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: United Kingdom: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: United Kingdom: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Italy: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Italy: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Spain: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Spain: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Russia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Russia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Latin America: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Latin America: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Brazil: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Brazil: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Mexico: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Mexico: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Middle East and Africa: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Middle East and Africa: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: RNA Interference (RNAi) Drug Delivery Industry: SWOT Analysis
  • Figure 80: Global: RNA Interference (RNAi) Drug Delivery Industry: Value Chain Analysis
  • Figure 81: Global: RNA Interference (RNAi) Drug Delivery Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: RNA Interference (RNAi) Drug Delivery Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 3: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 4: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: RNA Interference (RNAi) Drug Delivery Market Structure
  • Table 6: Global: RNA Interference (RNAi) Drug Delivery Market: Key Players
目次
Product Code: SR112024A2758

The global RNA interference (RNAi) drug delivery market size reached US$ 84.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 410.3 Billion by 2032, exhibiting a growth rate (CAGR) of 18.7% during 2024-2032.

Ribonucleic acid interference (RNAi) drug delivery refers to a therapeutic solution to monitor gene expression or mutations. RNAi drug delivery is usually administered through intravenous, intra-dermal and intraperitoneal injections and topical delivery methods. It involves nanoparticle, pulmonary, nucleic acid and aptamer drug delivery technologies. These technologies are also used for analyzing gene functions in eukaryotes and developing therapeutic gene silencing solutions. As a result, RNAi drug delivery is widely used for treating infectious diseases, chronic metabolic disorders, cardiovascular, neurological, urological, oncological and ophthalmological disorders.

The increasing prevalence of chronic medical and genetic disorders, such as cancer and cardiovascular diseases (CVDs) across the globe, represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for RNAi drug delivery technologies. Targeted delivery methods, such as aptamer drug delivery systems, are gaining immense traction for the administration of antiviral drugs as they are induced by small interfering RNA (siRNA) that can inhibit the expression of viral antigens. Additionally, various technological advancements, such as the development of innovative synthetic delivery carriers and bio-vectors, are anticipated to drive the market growth. The nanocarriers, including siRNA or microRNAs (miRNA), are crucial for developing personalized medicines and identifying altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global RNA interference (RNAi) drug delivery market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on application and technology.

Breakup by Application:

Infectious Disease

Cardiology

Oncology

Neurology

Ophthalmology

Urology

Metabolic Disorders

Others

Breakup by Technology:

Nanoparticle Drug Delivery

Pulmonary Drug Delivery

Nucleic Acid Drug Delivery

Aptamer Drug Delivery

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac AG, Dicerna Pharmaceuticals Inc., Gradalis Inc., Ionis Pharmaceuticals Inc, Merck & Co. Inc., Moderna Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Silence Therapeutics Plc, and Sirnaomics Inc.

Key Questions Answered in This Report:

  • How has the global RNA interference (RNAi) drug delivery market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global RNA interference (RNAi) drug delivery market?
  • What are the key regional markets?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the technology?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global RNA interference (RNAi) drug delivery market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global RNA Interference (RNAi) Drug Delivery Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Application

  • 6.1 Infectious Disease
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Cardiology
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Oncology
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Neurology
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Ophthalmology
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Urology
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Metabolic Disorders
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Others
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Nanoparticle Drug Delivery
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Pulmonary Drug Delivery
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Nucleic Acid Drug Delivery
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Aptamer Drug Delivery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Alnylam Pharmaceuticals Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Arrowhead Pharmaceuticals Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
    • 13.3.3 CureVac AG
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
    • 13.3.4 Dicerna Pharmaceuticals Inc.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
    • 13.3.5 Gradalis Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 Ionis Pharmaceuticals Inc
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Merck & Co. Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Moderna Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
    • 13.3.9 Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
    • 13.3.10 Silence Therapeutics Plc
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
    • 13.3.11 Sirnaomics Inc.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio